Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis
This study assessed medical costs of early discontinuation of hypomethylating agents (HMAs) in patients with refractory anemia with excess blasts subgroup of myelodysplastic syndromes using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database (2010-2016). Patients discontinuing HMAs before the recommended time frame required to elicit clinical response may experience suboptimal outcomes and incur higher healthcare costs, thus pointing to the potential benefit of treatment continuity as per guidelines.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Namita Joshi, Hrishikesh Kale, Shelby Corman, Tim Wert, Kala Hill, Amer M. Zeidan Tags: Original Study Source Type: research
More News: Anemia | Databases & Libraries | Epidemiology | Healthcare Costs | Hematology | Kale | Leukemia | Lymphoma | Medicare | Myelodysplastic Syndrome | Myeloma | Study